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Abstract
Background: Alzheimer's disease (AD) is characterized by extensive loss of neurons in the brain
of AD patients. Intracellular accumulation of beta-amyloid peptide (Aβ) has also shown to occur in
AD. Neuro-inflammation has been known to play a role in the pathogenesis of AD.
Methods: In this study, we investigated neuro-inflammation and amyloidogenesis and memory
impairment following the systemic inflammation generated by lipopolysaccharide (LPS) using
immunohistochemistry, ELISA, behavioral tests and Western blotting.
Results: Intraperitoneal injection of LPS, (250 μg/kg) induced memory impairment determined by
passive avoidance and water maze tests in mice. Repeated injection of LPS (250 μg/kg, 3 or 7 times)
resulted in an accumulation of Aβ1–42 in the hippocampus and cerebralcortex of mice brains
through increased β- and γ-secretase activities accompanied with the increased expression of
amyloid precursor protein (APP), 99-residue carboxy-terminal fragment of APP (C99) and
generation of Aβ1–42 as well as activation of astrocytes in vivo. 3 weeks of pretreatment of sulindac
sulfide (3.75 and 7.5 mg/kg, orally), an anti-inflammatory agent, suppressed the LPS-induced
amyloidogenesis, memory dysfunction as well as neuronal cell death in vivo. Sulindac sulfide (12.5–
50 μM) also suppressed LPS (1 μg/ml)-induced amyloidogenesis in cultured neurons and astrocytes
in vitro.
Conclusion:  This study suggests that neuro-inflammatory reaction could contribute to AD
pathology, and anti-inflammatory agent could be useful for the prevention of AD.
Background
Alzheimer's disease (AD) is a progressive neuro-psychiat-
ric disorder. The major neuropathological hallmarks of
AD are the formation of senile plaques (SPs) following
neurofibrillary tangles (NFTs) which cause neuronal
degeneration and synaptic loss. SPs are extracellular
deposits of fibrillar and amorphous aggregates of amyloid
beta-peptide (Aβ) whereas NFTs are intracellular fibrillar
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aggregates of the microtubule-associated protein tau that
exhibit hyperphosphorylation. The formation of SPs and
NFTs in brain regions such as the entorhinal cortex, hip-
pocampus, basal forebrain and amygdala impaired learn-
ing and memory functions [1]. AD brains also exhibit a
number of pathological abnormalities, including a pro-
found loss of synapses, reactive gliosis, and inflammatory
processes [2].
The brain has an endogenous immune system that is coor-
dinated by immunocompetent cells such as microglia.
The brain is also vulnerable to constitutive defense
responses, such as inflammation [3,4]. The inflammation
associated with the brain, neuro-inflammation, differs
from that found in the periphery. Although edema and
neutrophil invasion, typical features of inflammation, is
not seen in the AD brain, tissue levels of inflammatory
mediators including cytokines, chemokines, oxygen free
radicals and reactive nitrogen species, are altered [5,6].
Numerous reports have indicated that neuro-inflamma-
tory process contributes to the pathogenesis of AD. Study
performed in transgenic animals suggest that neuro-
inflammation plays an important role in the process of
cerebral amyloid deposition [7]. It has been shown that
inflammatory cytokines such as Interleukin (IL)-1β, IL-6,
Tumor necrosis factor-αgTNF-α) or Transforming growth
factor-β (TGF-β) can augment APP expression [8,9] and
Aβ formation [10]. It was also reported that cytokines are
able to transcriptionally upregulate β-secretase mRNA,
protein and enzymatic activity [11]. β-secretase is a key
rate-limiting enzyme that initiates Aβ formation [12].
Without β-secretase, Aβ synthesis is either abolished or
considerably reduced [13]. Moreover, McGeer and Rogers
proposed possible therapeutic effects of anti-inflamma-
tory agents on the patients with AD [14]. Inflammatory
mediators present in AD lesions are thought to stimulate
underlying key events of the pathological cascade that
result in increased Aβ production with recruitment and
activation of microglial cells [15].
Many persons with AD die with systemic inflammation
such as a lung or bladder infection. The systemic inflam-
mation will lead to the generation of circulating
cytokines, which will have in turn an impact on the cen-
tral nervous system [16]. Furthermore, it was also reported
that intraperitoneal injection of lipopolysaccharide (LPS)
induces cognitive impairment in mice [17,18]. However,
underlying mechanisms involved in LPS induced cogni-
tive impairment are not known. To investigate the impact
of systemic inflammation on memory impairment and its
role in cortical amyloid formation and deposition, mice
were intraperitoneally injected with LPS to generate sys-
temic inflammation, and then investigated for the possi-
ble mechanisms of LPS-induced memory impairment and
amyloidogenesis in vivo and in vitro.
Methods
Animals
Male ICR mice (Damool Science, Korea) weighing 25–30
g and Sprague-Dawley rats weighing 200–300 g, were
used in all experiments. Animals were maintained in
accordance with the National Institute of Toxicological
Research, Korea Food and Drug Administration guide-
lines for the care and use of laboratory animals. Animals
were housed in two cages (five per cage) and in a 22 ± 2°C
and 45~65% relative humidity environment under a 12-
hr light/12-hr dark cycle (8:00 a.m. ~8:00 p.m.). All ani-
mals had free access to food (Samyang Foods, Seoul,
Korea) and water. The anti-inflammatory sulindac sulfide
(3.75 or 7.5 mg/kg) was given orally for 3 weeks prior to
the injection of LPS in in vivo study.
The mice were randomly divided within each cage and
injected intraperitoneally with either 250 μg/kg of
Lipopolysaccharide (LPS) or sterile saline (0.9% NaCl).
For all experiments, LPS (Escherichia coli, serotype 055:B5,
Sigma, St. Louis, MO, USA) was used to induce an inflam-
matory response and was injected once on day 1 of behav-
ioral testing. All injections were administered 4 hrs prior
to testing. This allows enough time for the development
of neuro-inflammation expressing central IL-1β gene
(most notably in circumventricular organs, meningeal tis-
sue, and choroid plexus) at this dose and similar doses of
intraperitoneal LPS [19].
Behavioral test
1. Passive avoidance test (Step-through test)
The passive avoidance test is a widely accepted simple and
rapid means of memory testing. Passive avoidance
response was determined using a "step-through" appara-
tus (Med Associated Inc., St. Albans, VT, USA), which con-
sisted of an illuminated and dark compartment (each
20.3 × 15.9 × 21.3 cm) adjoining each other through a
guillotine door. Floors were constructed of 3.175 mm
stainless steel rods set 8 mm apart. The test was conducted
for 2 consecutive days at the same time each day. On the
first day (learning trial) each mouse was placed in the illu-
minated compartment facing away from the dark com-
partment. Once the mouse enters completely into the
dark compartment, it receives an electric shock (1 mA, 3
s) through the stainless steel grid floor. The amount of
time it took for the mouse to enter into the dark compart-
ment was recorded automatically, and described as step-
through latency. On the second day (testing trial), the
same test procedure was followed. When the mouse did
not enter the dark compartment within 300s, the test was
terminated and a latency of 300s was recorded.Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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2. Water maze test
The water maze test was performed as described by Morris
et al. [20] using the SMART-CS (Panlab, Barcelona, Spain)
program and equipment. A circular pool (height: 35 cm,
diameter: 100 cm) was filled with water, dyed black by
dissolving food colorings and maintained at 22~25°C. An
escape platform (height: 14.5 cm, diameter: 4.5 cm) was
then submerged 0.5~1 cm below the surface of the water
in the northeastern quadrant of the pool. On training tri-
als, the mice were placed in the pool of water and allowed
to remain on the platform for 10 s and were then returned
to their cage during the second-trial interval. The mice that
did not find the platform within 120 s were placed on the
platform for 10 s at the end of trial. 24 hrs after 6 trials
(two times per day for 3 days), mice were given LPS. Four
hrs after the treatment of LPS (designated as day 1), they
were allowed to swim until they sought the escape plat-
form. Escape latency, escape distance, swimming speed
and swimming pattern of each mouse was monitored for
3 days (1 time/day) by a camera above the center of the
pool connected to a SMART-LD program (Panlab, Barce-
lona, Spain).
Tissue preparation
After the behavioral tests, animals were perfused with PBS
under inhaled diethyl ether anesthesia. Brains were imme-
diately collected, stored at -20°C, and separated into cor-
tical and hippocampal regions. The brain regions
(hippocampus and cerebralcortex) were immediately
stored at -80°C before an assay of secretase activities, Aβ1–
42 level as well as western blotting.
Astrocyte culture
As described elsewhere [21,22], 2-day-old rat pups were
ice-anesthetized and decapitated. After the skin was
opened and the skull was cut, the brain was released from
the skull cavity. After washing with PBS, the cerebrum was
separated from the cerebellum and brain stem, and the
cerebral hemispheres were separated from each other by
gently teasing along the midline fissure with the sharp
edge of forceps. The meninges were gently peeled from the
individual cortical lobes and the cortices were dissociated
by mechanical digestion [using the cell strainer (BD Bio-
sciences, Franklin Lakes, NJ, USA)] with Dulbecco's mod-
ified Eagle's medium (DMEM) containing F12 nutrient
mixture (Invitrogen, Carlsbad, CA). The resulting cells
were centrifuged (1,500 rpm, 5 mins), resuspended in
serum-supplemented culture media, and plated into 100
mm dishes. Serum-supplemented culture media was com-
posed of DMEM supplemented with F12, FBS (5%),
NaHCO3 (40 mM), penicillin (100 units/ml), and stepto-
mycin (100 μg/ml). The cells were incubated in the cul-
ture medium in a humidified incubator at 37°C and 5%
CO2for 9 days. At confluence (9 days), the flask was sub-
jected to shaking for 16–18 hrs at 37°C. The cultures were
treated for 48 hrs with cytosine arabinoside and the
medium was replaced with DMEM/F12HAM containing
10% FBS. The monolayer was treated with 1.25% trypsin-
EDTA for a short duration after which the cells were disso-
ciated and plated into uncoated glass coverslips. The
astrocyte cultures formed a layer of process-bearing,
GFAP-positive cells. The purity of astrocyte cultures was
assessed by GFAP-immunostaining. Under these condi-
tions, we can assume that over 95% of the cells were astro-
cytes. The cultured cells were treated with LPS or TNF-α or
IFN-γ for 24 hrs, and cells were harvested for the assay of
Aβ and western blotting.
Embryonic neuronal cell culture
The Sprague-Dawley pregnant rats were sacrificed by cer-
vical dislocation and the embryos were removed on the
18th day of gestation. The embryonic brain tissues were
mechanically dissociated into individual cells in NEURO-
BASAL medium (Invitrogen, Carlsbad, CA, USA). The
resulting cells were centrifuged (1,500 rpm, 5 min), resus-
pended in NEUROBASAL medium containing B-27 sup-
plement (Invitrogen, Carlsbad, CA), L-glutamine (0.5
mM), penicillin (100 units/ml), steptomycin (100 μg/ml)
and plated into 60 mm dishes. The culture media was
changed every 2 days. Greater than 90% of the cells in
these cultures were neurons as assessed by cell morphol-
ogy and immunostaining with mouse monoclonal anti-
bodies against neurofilaments (1: 5,000). 7 day cultured
cells were treated with LPS or TNF-α or IFN-γgor 24 hrs,
the cells were harvested for the assay of Aβ and western
blotting.
Western blotting
Brain tissues and cells were homogenized with protein
extraction solution (PRO-PREP™, Intron Biotechnology,
Korea), and lysed by 60 min incubation on ice. The lysate
was centrifuged at 15,000 rpm for 15 min. Equal amount
of proteins (40 μg) were separated on a SDS/10% or 15%-
polyacrylamide gel, and then transferred to a polyvinyli-
dene difluoride (PVDF) membrane (GE Water & Process
technologies, Trevose, PA, USA). Blots were blocked for 2
hrs at room temperature with 5% (w/v) non-fat dried milk
in Tris-Buffered Saline Tween-20 [TBST: 10 mM Tris (pH
8.0) and 150 mM NaCl solution containing 0.05% tween-
20]. After a short wash in TBST, the membrane was incu-
bated at room temperature with specific antibodies. Rab-
bit polyclonal antibodies against iNOS and COX-2 (1:
1,000 dilution, Cayman Chemical, Ann Arbor, MI, USA),
APP (1:500 dilution, ABR, Golden, CO, USA), BACE1
(1:500 dilution, Sigma, St. Louis, MO, USA), C99 (1:500
dilution, Sigma, St. Louis, MO, USA) and mouse mono-
clonal antibody against phospho-ERK (1:500 dilution,
Santa Cruz Biothechnology Inc. Santa Cruz, CA, USA)
were used in the study. The blot was then incubated with
the corresponding conjugated anti-rabbit or mouseJournal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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immunoglobulin G-horseradish peroxidase (1:2,000
dilutions, Santa Cruz Biotechnology Inc. Santa Cruz, CA,
USA). Immunoreactive proteins were detected with the
BM Chemiluminescence blotting substrate (Roche
applied science, Mannheim, Germany).
Immunohistochemistry and immunofluorescence
Mice were euthanized with diethyl ether and perfused
with 0.1 M PBS then with 4% paraformaldehyde. The
brains were collected from mice following perfusion and
immediately fixed in 4% paraformaldehyde for 24 hrs.
The brains were transferred successively to 10%, 20% and
30% sucrose solutions. Subsequently, brains were frozen
on a cold stage and sectioned in a cryostate (40 μm-thick).
Sections were treated with endogenous peroxidase (3%
H2O2 in PBS), and then with 0.01 M PBS blocking buffer
containing 10% bovine serum albumin in PBS for 40 min.
Then the sections were incubated with rabbit polyclonal
antibody against Aβ1–42 (1:2,000 dilution, Covance, Ber-
keley, CA, USA), and iNOS and COX-2 (1: 1,000 dilution,
Cayman Chemical, Ann Arbor, MI, USA), overnight. After
the incubation, sections were washed in PBS and incu-
bated with the biotinylated secondary antibodies (ABC
kit, Vector Laboaratories, Burlingame, CA) for 30 min.
The sections were washed with PBS, incubated with the
avidin-biotin complex (Vector Laboratories, Burlingame,
CA) for 30 min, and visualized by chromogen DAB (Vec-
tor Laboratories, Burlingame, CA) reaction. The sections
were dehydrated in ethanol, cleared in xylene, and
mounted with permaunt (Fisher Scientific, Hampton,
NH). For the detection of cellular location of Aβ1–42, we
did an immunofluorescence immunostaining. Sections
were rinsed in 0.01 M PBS buffer. After washing in PBS,
the sections were incubated for 1 hr at room temperature
with 10% bovine serum albumin diluted in PBS. The sec-
tions were incubated overnight at 4°C with Rabbit Poly-
clonal Aβ1–42  antibody (1:2000 dilution, Covance,
Berkeley, CA, USA). After washing in PBS, the sections
were washed and incubated with Alexa Fluro 568 conju-
gated Rabbit Polyclonal antibody (1:200 dilution, Molec-
ular Probe, Carlsbad, CA, USA) for 2 hrs at room
temperature. Next, the sections were incubated with DAPI
for 15 min at 37°C. Finally, the sections were rinsed,
mounted on slides, and coverslipped for fluorescence
microscopy and photography using ApoTome microscope
(Carl Zeiss, Inc., Thornwood, NY, USA). For detection of
apoptotic cell death in tumor tissue, the paraffin embed-
ded sections were then incubated in the mixture of labe-
ling solution (450 μl) and enzyme solution (50 μl) for 1
hr at 37°C and washed 3 times in 0.1 M PBS for 5 min
each according to manufacturer's instructions. Next, the
sections were incubated with DAPI for 15 min at 37°C.
Finally, the sections were rinsed, mounted on slides, and
coverslipped for fluorescence microscopy (DAS micro-
scope). Positive TUNEL stains were recorded by counting
the number of positively stained DAPI in the definite area.
α-, β- and γ-secretase activity assays
The total activities of α-, β- and γ-secretase present in cor-
tical and hippocampal regions were determined using a
commercially available α-secretase activity kit (R&D sys-
tems, Wiesbaden, Germany), β-secretase fluorescence res-
onance energy transfer (BACE 1 FRET) assay kit
(PANVERA, Madison, USA) and γ-secretase activity kit,
(R&D systems, Wiesbaden, Germany) according to the
manufacturer's instructions, respectively. Each tissue was
homogenized in cold 1 × cell extraction buffer (a compo-
nent of the kit) to a final protein concentration of 1 mg/
ml.
To determine α (or γ)-secretase activity, 50 μl of lysate was
mixed with 50 μl of reaction buffer. The mixture was incu-
bated for 1 hr in the dark at 37°C after 5 μl of substrate
was added. Substrate conjugated to the reporter molecules
EDANS and DABCYL was cleaved by α (or γ)-secretase
and released a fluorescent signal. This fluorescence was
measured using a Fluostar galaxy fluorometer (excitation
at 355 nm and emission at 510 nm) equipped with Felix
software (BMG Labtechnologies, Offenburg, Germany).
The level of α (or γ)-secretase enzymatic activity was pro-
portional to fluorescence with the intensity of fluorescene
which was expressed as fluorescence units.
To determine β-secretase, 10 μl of lysate was mixed with
10 μl of BACE1 substrate (Rh-EVNLDAEFK-Quencher).
The reaction mixture was then incubated for 1 hr at room
temperature in a black 96-microwell plate. The reaction
was stopped by adding 10 μl of BACE1 stop buffer (2.5 M
sodium acetate). Fluorescence was determined using a
Fluostar galaxy fluorometer (excitation at 545 nm and
emission at 590 nm) equipped with Felix software (BMG
Labtechnologies, Offenburg, Germany). Enzyme activity
was linearly related to fluorescence increases, and the
activity was expressed as fluorescence units. All controls,
blanks and samples were run in triplicate.
Measurement of Aβ level
Lysates of brain tissue prepared as described in the West-
ern blotting section were obtained through protein extrac-
tion buffer containing protease inhibitor. Media from
neuronal cell culture was collected, then briefly spun to
remove cell debris and mixed with 4-(2-aminoethyl)-ben-
zene sulfonyl fluoride serine protease inhibitor. Aβ1–42
and Aβ1–40 levels were determined using specific ELISAs
(IBL, Immuno-Biological Co., Ltd., Japan). In short, 100
μl of sample was added into the precoated plate and was
incubated overnight at 4°C. After washing each well of the
precoated plate with washing buffer, 100 μl of labeled
antibody solution was added and the mixture was incu-Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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bated for 1 hr at 4°C in the dark. After washing, chro-
mogen was added and the mixture was incubated for 30
mins at room temperature in the dark. After the addition
of stop solution, the resulting color was assayed at 450 nm
using a microplate absorbance reader (Sunrise™, TECAN,
Switzerland).
Statistics
The experimental results were expressed as mean ± S.E. A
one-way analysis of variance (ANOVA) was used for mul-
tiple comparisons followed by Dunnett. Differences with
P < 0.05 were considered statistically significant.
Results
LPS induced memory impairment
In the passive avoidance test, at the learning trial (day 0),
mice of all groups entered the dark compartment, and
there were no significant differences among the animals.
However, in the testing trial (day 1), the mice which
received a single intraperitoneal injection of LPS (250 μg/
kg) showed a significantly reduced step-through latency
compared to those injected with vehicle (Fig. 1A). In the
water maze test, the mice exhibited progressively
decreased escape latency by the training (3 days after
training; 2 times/day, total of 6 times training), and the
escape latency at the end of training (7th escape latency) to
the platform was about 403 ± 44 cm and 19 ± 1 s (data not
shown). LPS was then administered into the mice. Similar
to the result in the step through test, LPS-treated mice
Effect of LPS on step-through type passive avoidance test (A) and water maze test (B, C, D) Figure 1
Effect of LPS on step-through type passive avoidance test (A) and water maze test (B, C, D). (A), Each value is mean ± S.E. 
from 7–9 mice. *Significantly different from control (p < 0.05). Memory function was determined by the escape latencies (B, 
sec), distance (C, cm) and speed (D, cm/sec) for 3 days at 4 hr (designated 1 day) after administration of LPS. Each value is 
mean ± S.E. from 7–9 mice. *Significantly different from control (p < 0.05).Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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showed longer escape latency (the time required to find
the platform) and escape distance (the distance swam to
find the platform) than the control group (Fig. 1B). This
tendency continued throughout the 3-day trial period
although the difference between the two groups was get-
ting smaller. The LPS-treated group traveled a further dis-
tance to reach the platform than the control group did
(Fig. 1C). It is considered that these differences between
the two groups reflected the difference in memory func-
tion since there was not much difference in swimming
speed (Fig. 1D).
LPS induced Aβ generation in mice brains
A single intraperitoneal injection of LPS increased the
Aβ1–42 level in the cortex and hippocampus (Fig. 2A). In
contrast, a single intraperitoneal injection of LPS
decreased the Aβ1–40 level in the cortex and hippocampus
(Fig. 2A). To assess the pattern of Aβ1–42 deposition, we
analyzed the Aβ1–42 immunoreactivity in the cortex and
hippocampus following daily LPS injections for 3–7 days.
An increase of Aβ1–42 immunoreactivity was observed in
the LPS injected group compared to that of the control
group (Fig. 2B). Aβ1–42 immunoreactivity progressively
increased with the duration of LPS adminstration and was
Effect of LPS on Aβ accumulation in the cortex and hippocampus Figure 2
Effect of LPS on Aβ accumulation in the cortex and hippocampus. The levels of Aβ1–42 and Aβ1–40 (A) were assessed 
by using a specific Aβ ELISA as described in the Materials and methods section. Values measured from each group of mice were 
calibrated by amount of protein and expressed as mean ± S.E. (n = 5) *Significant different from control (p < 0.05). Immunos-
taining of Aβ1–42 in the cortex and hippocampus (B). Mice were injected intraperitoneally with either 250 μg/kg LPS or sterile 
saline (0.9% NaCl) daily for 3 or 7 days before sacrifice. Forty μm-thick sections of brains from mice were incubated with rab-
bit polyclonal anti-Aβ1–42 antibody and counterstained with hematoxylin. Arrow indicates Aβ1–42 accumulation which is clearly 
higher in the cerebral cortex and hippocampus of LPS-treated mouse and was the highest in the mouse treated with daily injec-
tion for 7 days. Figure in box shows the intracellular accumulation of Aβ1–42 (detected anti-Aβ1–42 immunofluroscene staining 
after DAPI staining the cells) in the pyramidal neurons of the hippocampus at the high magnification. Arrow bar indicates accu-
mulation of Aβ1–42.Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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much more intense in the hippocampus compared to the
control.
LPS decreased α-secretase activity but increased βg and γ-
secretase activities as well as expression of APP, BACE and 
C99 proteins in mice brains
Following a single injection of LPS, the activities of β and
γ-secretase in the cortex and hippocampus increased (Fig.
3B and 3C), whereas, the activity of α-secretase decreased
in mice brains (Fig. 3A). Moreover, LPS treatment
increased expression of APP, BACE and C99 accompanied
with the increase of inflammatory proteins iNOS and
COX-2 expression (Fig. 3D).
Inflammatory agents promoted amyloidogenesis in vitro
It is known that microglia and astrocytes are major
sources of neuro-inflammation. Moreover, recent data
showed that neuronal cells also have cytokine receptors
such as LPS receptor (toll like receptor) as well as TNF
receptor [23,24]. Neurons may be directly involved in
neuro-inflammation or indirectly via the interaction with
microglia and astrocytes. In order to analyze the effect of
LPS induced inflammation on amyloidogenesis in vitro,
cultured astrocytes from rat pups and neuronal cells from
rat embryos were used. Astrocytes lend both mechanical
and metabolic support for neurons, regulating the envi-
ronment in which they function. Interferron-gamma
(IFN-γ) and tumor necrosis factor-alpha (TNF-α) as well
as LPS were treated to induce an inflammatory reaction.
Effect of LPS on secretase activities and amyloidogenic proteins expression Figure 3
Effect of LPS on secretase activities and amyloidogenic proteins expression. The activities of α-, β-secretase (A, B) 
and γ-secretase (C) were assessed by using commercially available assay kits. Data represent mean ± S.E. (n = 5). *Significant 
different from control group (p < 0.05). The expression of APP, BACE and C99 (D) were detected by Western blotting using 
specific antibodies. Each blot is representative for five experiments. β-actin protein was used here as an internal control.Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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Similiar to the in vivo results, inflammatory stimuli con-
comitantly increased expression of amyloidogenic pro-
teins (such as APP, BACE and C99) accompanied with the
increase of expression of inflammatory proteins (such as
COX-2 and iNOS) in both astrocytes (Fig. 4A) and neuro-
nal cells (Fig. 4B). These results further indicate amy-
loidogenic pathway could be promoted by neuro-
inflammatory stimulation in in vitro and in vivo.
Anti-inflammatory drug inhibited LPS-induced 
amyloidogenesis and memory impairment
The effect of sulindac sulfide, a COX-1, 2 non-selective
drugs, in vivo and in vitro system was assessed. Sulindac
sulfide has been known to decrease the Aβ secretion in
N2a neuroblastoma cells stably transfected with human
APP695 bearing the Swedish mutation [25]. As shown in
Fig. 4C, the cells expressed low levels of APP, β-site APP
cleavage enzyme (BACE) and C99 protein in an unstimu-
lated condition, whereas, expression of BACE, APP and
C99 proteins increased in response to LPS (1 μg/ml) after
24 hrs. Treatment with sulindac sulfide (12.5, 25, 50 μM)
Effect of anti-inflammatory agents on expression of amyloidogenic proteins (A, B) Figure 4
Effect of anti-inflammatory agents on expression of amyloidogenic proteins (A, B). The expression of APP, BACE and C99 
were detected by Western blotting using specific antibodies in astrocytes (A) and neuronal cells (B). β-Actin protein was used 
as an internal control. Each blot is representative for five experiments. Sulindac sulfide inhibits expression of amyloidogenic 
proteins (C) and Aβ1–42 secretion (D) induced by LPS in cultured neuronal cells. Combined Sulindac sulfide (12.5, 25, 50 μM) 
and LPS treatment for 24 hr were used. (C), The expression of APP, BACE and C99 in neuronal cells was detected by West-
ern blotting using specific antibodies. β-Actin protein was used as an internal control. (D), Media were collected to determine 
an Aβ1–42 secretion by ELISA. Data represent mean ± S.E. of three experiments with duplicated. *Significant different from LPS 
treated group (p < 0.05).Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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caused concentration-dependent decreases in LPS-
induced BACE, and C99 expression in neuronal cells, but
did not change the expression of APP. In addition, sulin-
dac sulfide decreased LPS-induced Aβ1–42 secretion into
culture media (Fig. 4D). Furthermore, oral pretreatment
with sulindac sulfide (3.75 and 7.5 mg/kg) for 3 weeks
suppressed memory impairment caused by LPS, and
reduced increased Aβ1–42 levels (Fig. 5D) in concentra-
tion-dependent manners. This was evaluated with the pas-
sive avoidance test (Fig. 5A) and the water maze test (Fig.
5B and 5C). It is considered that sulindac sulfide may
have an endogenous Aβ-lowering effect in neuronal cells,
and suggests that inflammatory reaction could influence
the amyloidogenesis, and thus could improve memory
function.
LPS caused neuronal cell death in the brain
To verify the relationship between LPS-induced accumula-
tion of Aβ and neuronal cell death, we investigated the
induction of cell death by LPS in vivo. Substantial increase
of apoptotic cells was found in the hippocampus of LPS
treated mice. A significant increase in the percentage of the
Effect of sulindac sulfide on the LPS-induced memory impairment (A-C) and elevated Aβ1–42 level (D) Figure 5
Effect of sulindac sulfide on the LPS-induced memory impairment (A-C) and elevated Aβ1–42 level (D). Sulindac sulfide was pre-
treated for 3 weeks by oral administration. For the passive avoidance performance test, mice were trained one time. At 24 hr 
later, mice were given LPS (250 μg/kg, i.p.). After 4 hr treatment of LPS, the latency period was measured. Each value is means 
± S.E. from 15 mice. *Significantly different from LPS treated control (p < 0.05). (B-C), Mice were pretreated with Sulindac 
sulfide for 3 weeks, and then trained for 3 days (2 times/day, 6 times training), and then LPS (250 μg/kg, i.p.) was administered 
into mice. Memory function was determined by the escape latencies (cm, B) and distance (sec, C) at 4 hr (designated day 1). 
Each value is means ± S.E. from 15 mice. D, The levels of Aβ1–42 were assessed after finishing the behavioral tests by using a 
specific Aβ1–42 ELISA. Values measured from each group of mice were calibrated by amount of protein and expressed as mean 
± S.E. (n = 15) *Significant different from LPS treated group (p < 0.05).Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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number of apoptotic cells was detected in the LPS treated
animals (36.2 ± 3.6%) verses the control (2.1 ± 0.8%).
The percentage of the number of apoptotic cells in the
brains of LPS treated animals was significantly reduced by
the sulindac sulfide pretreatment. The values were 11.4 ±
2.8% (3.75 mg/kg), and 6.1 ± 1.8% (7.5 mg/kg), respec-
tively (Fig. 6A).
The activation of astrocytes was analyzed by their immu-
noreactivity for GFAP which was more intensive in LPS
treated mice brains than in controls. It was also reduced
by sulindac sulfide pre-treatment (Fig. 6B).
Discussion
Epidemiological and genetic evidences have shown that
an inflammatory process may contribute to AD pathol-
ogy. However, the exact relationship and mechanisms are
not clear. Therefore, we tried to establish a convincing the-
oretical link between neuro-inflammatory reaction and
amyloidogenesis. Our results demonstrated that systemic
injections of LPS induced memory impairment. LPS also
Effect of LPS on activation of astrocytes (A) and apoptotic cell death (B) Figure 6
Effect of LPS on activation of astrocytes (A) and apoptotic cell death (B). Mice were injected intraperitoneally with either 250 
μg/kg LPS or sterile saline (0.9% NaCl) daily for 7 days before sacrifice. Forty μm-thick sections of brains from mice were 
immunostained with rabbit polyclonal anti-GFAP antibody for evaluation of activation of astrocytes. The broad distribution and 
deep intensity of GFAP reactive cells increased in the LPS injected mice brain. Each panel is representative of 6 animals. Apop-
totic cell death was determined by DAPI staining and TUNEL assay. Apoptosis (%) was defined as the percentage of the 
number of TUNEL-positive cells per surface of unit. Values are mean ± S.E. (n = 6). *P < 0.05 indicates significantly different 
from LPS-treated cells.Journal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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induced Aβ1–42 generation in both the cortex and hippoc-
ampus. In in invo and in vitro studies, expression of the
genes involved in inflammation and in amyloidogenesis
was also concomitantly increased by the LPS treatment.
Moreover, the anti-inflammatory drug sulindac sulfide
inhibited the LPS-induced memory impairment and amy-
loidogenesis. These results indicate that systemic inflam-
mation induced by LPS could cause memory impairment
through enhancement of amyloidogenesis.
Recent studies have demonstrated that LPS influences Aβ
deposition [25], and anti-inflammatory agents prevent Aβ
deposition [26]. Ibuprofen, a commonly used nonsteroid
anti-inflammatory drug, decreased cytokine-stimulated
Aβ production in human neuronal cells and astrocytes
[27]. It also reduced Aβ levels and brain inflammation in
Tg2576 AD mice [28]. Indometacin given to Tg2576 mice
also reduced insoluble Aβ1–42 in the hippocampus [29].
Our previous data also showed a co-elevated expression of
Aβ1–42 and COX-2 as well as IL-1 in presenlinin 2 mutant
AD transgenic mice [30]. Our present study demonstrated
that co-expression of inflammatory proteins COX-2 and
iNOS, and amyloidogenic proteins BACE and C99 was
higher in the LPS-treated mice brains, and LPS alone or
LPS with IFN-γ or TNF-α treated cultured astrocytes and
neuronal cells. However, the anti-inflammatory drug
sulindac sulfide decreased the LPS-induced expressions of
BACE and C99 as well as COX-2 and iNOS. These data
indicate that expression of inflammatory proteins could
be linked with expression of the proteins related with
amyloidogenesis. We also found that LPS treated brains
showed higher levels of Aβ1–42 but lower levels of Aβ1–40.
It may be interesting to note that several other investiga-
tors demonstrated that Aβ1–40 could be cytoprotective.
Kuperstein et al. reported that Aβ1–40 protects fetal rat
brain from intrauterine ischemic stress [31]. Zou et al. also
demonstrated that Aβ1–40 protects neurons from damage
induced by Aβ1–42 in culture and in rat brains [32] via serv-
ing as an antioxidant molecule against metal-induced oxi-
dative damage [33]. This increase of Aβ1–42  with
concomitant decrease of Aβ1–40could be related with the
elevation of the expression of amyloidogenic proteins in
LPS-treated mice brains, and could also be involved in
neuronal damages causing memory dysfunction. Very
similar to our findings, Hauss-Wegrzyniak and Wenk
showed that LPS induced extracellular deposition of beta-
amyloid fibrils into the hippocampus [34]. Therefore, our
results suggest that there is a close connection between
amyloidogenesis and neuro-inflammation induced by
systemic injection of LPS, and thus neuro-inflammation
enhances Aβ generation which impairs memory function.
The way LPS induces amyloidogenesis is not clear. How-
ever, it could be related with the change in secretase activ-
ities. APP is first cleaved by β-secretase at its β-cleavage site
generating a membrane bound C99 whose subsequent
proteolysis by a second enzyme, γ-secretase produces Aβ1–
42. Thus, we determined secretase activities. Consistent
with the increasing effect on Aβ1–42 generation and expres-
sion of APP, BACE and C99, LPS treatment increased β-
and γ-secretase activities. It has been shown that inflam-
matory cytokines IL-1β, IL-6, TNF-α and TGF-β aug-
mented APP expression [8,9], and Aβ formation [10], and
these processes may be related with the activation of tran-
scriptional upregulation of β-secretase mRNA, protein
and enzymatic activity [11]. It has also been observed that
TNF-α, IL-1β and IFN-γ stimulate γ-secretase so as to con-
trol Aβ generation [35]. Sheng et al. also reported that the
systemic injection of LPS increases APP expression and
processing with accumulation of Aβ in APPswe transgenic
mice [36]. LPS-induced increase of APP level in the
present study is in agreement with the observation by Rog-
ers et al. [37] who demonstrated that the primary inflam-
matory cytokine enhanced APP gene expression at the
translational level through the well characterized IL-1
responsive element of APP mRNA. Taken together, these
data indicated that LPS-enhanced inflammatory reactions
could influence APP processing through the enhancement
of β and γ-secretase activities, thereby affecting amyloido-
genesis. Bandyopadhyay et al. showed that cytokine inter-
leukin-1α stimulates non-amyloidogenic pathway by the
alpha-secretase (ADAM-10 and ADAM-17) cleavage of
APP in human astrocytes [38]. It was observed that IL-1β
induced sAPPα release via α-secretase cleavage in neurog-
lioma U251 cells [39]. We also found that LPS decreased
α-secretase. These findings suggest that one of other
mechanism increasing of β-amyloid by LPS may be in part
due to the inhibition of α-secretase activity.
The signals in LPS treatment induced amyloidogenesis
could be involved with the activation of AP-1 since APP
gene promoter contains potential activator protein-1 (AP-
1) recognition site [40-42], and LPS could activate AP-1
activity [43]. Activation of the MAP kinase pathway may
relay the amyliodogenesis signal as demonstrated in other
studies [44,45,30,46] in which MAP kinase plays a role in
neuro-inflammatory and neurodegenerative pathology of
relevance to AD. In the present study, it was also found
that phosphorylation of ERK, a type of MAP kinase, was
elevated in the LPS treated group, and sulindac sulfide
decreased the activation of ERK and Aβ1–42 secretion in
neuronal cells (data not shown). These data indicate that
ERK/AP-1 signal pathway may be important in the LPS-
induced amyloidogenesis.
The consequence of elevated Aβ1–42 by LPS could cause
neuronal cell death, and this may be associated with
memory impairment. In fact, we found that LPS-treated
mice brains showed increased number of cell death in
vivo. However, treatment of sulindac sulfide inhibitedJournal of Neuroinflammation 2008, 5:37 http://www.jneuroinflammation.com/content/5/1/37
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LPS-induced neuronal cell death, suggesting that induc-
tion of neuronal apoptotic cell death by LPS may directly
result from the induction of amyloidogenesis by neuro-
inflammation. Noble et al. reported that acute systemic
inflammation induces central mitochondrial damage and
amnesic deficit in adult Swiss mice [47]. Sparkman [17],
and Milatovic et al. [48] and Szczepanik and Ringheim
[49] reported that intraperitoneal injections of LPS cause
AD-like neuronal degeneration. We have also found that
mutant presenilin 2 (a genetic AD model) mice brains
showed increased inflammation and accumulation of Aβg
accompanied by an increase of apoptotic neuronal cell
death. LPS induced neuro-inflammatory signal activation
(Cox-2 and ERK activation) could be involved in the LPS-
induced neuronal cell death. Jang and Surh showed that
beta-amyloid-induced apoptosis is associated with
cyclooxygenase-2 up-regulation through activation of NF-
κB, which is mediated by upstream kinases including ERK
and p38 MAPK [50]. We also previously demonstrated
that Bcl-2 overexpression protects neuronal cells against
Aβ-induced cell death in differentiated PC12, and its pro-
tective effect was related to the reduction of Aβ-induced
activation of p38 MAP kinase [51]. Even though the exact
signal pathways in the LPS-induced neuronal cell death
and amyloidogenesis are not clear, the increase of apop-
totic neuronal cell death via the elevation of Aβ1–42 could
be an important mechanism in LPS-induced memory
impairment. The activation of astrocytes by treatment
with LPS may induce several cytotoxic cytokines which
could also hurt neighboring neuronal cells via directly
killing mechanisms [52-54] or via elevation of Aβ1–42
[9,10]. In conclusion, systemic inflammation by treat-
ment with LPS causes elevation of amyloidogenesis and
neuronal cell death which finally result in memory
impairment.
Conclusion
In conclusion, our current study showed that systemic
inflammatory stimuli elevated amyloidogenesis through
activation of β- and γ-secretases accompanied with inhibi-
tion of α-secretase leading to elevated Aβ1–42 levels in vivo
and in vitro. This co-elevated inflammation and amyloido-
genesis resulted in neuronal cell death, and thus memory
impairment. Moreover, the anti-inflammatory drug sulin-
dac sulfide inhibited both amylodogenesis and neuro-
inflammation which led to recovery effects on the LPS-
induced memory impairment. Therefore, the present data
suggest that systemic inflammation could be involved in
the development and/or progression of AD, and anti-
inflammatory drugs might be useful for the prevention of
AD.
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